Patients with metastatic castration-resistant prostate cancer (mCRPC) and visceral metastases have a worse prognosis than those with nonvisceral metastases. Treatment with the androgen receptor inhibitor enzalutamide in the phase 3 AFFIRM trial led to significant improvements in outcomes for patients with mCRPC. For the current report, the authors analyzed the efficacy of enzalutamide among patients from the AFFIRM trial who had visceral disease. METHODS: Patients who had liver and/or lung metastases at baseline were selected for prespecified overall survival (OS) and exploratory post hoc analyses, including prostate-specific antigen (PSA) response and the time to PSA and radiographic progression. RESULTS: In patients who had liver metastases (n 5 92), enzalutamide was associated with a lower risk of radiographic progression (hazard ratio [HR], 0.645; 95% confidence interval [CI], 0.413-1.008), improved 12-month OS (37.7% vs 20.6%) and radiographic progression-free survival (rPFS) (11.6% vs 3.0%) rates, and higher PSA response rates (35.1% vs 4.8%) compared with placebo. Enzalutamide-treated patients who had lung metastases (n 5 104) had improved median OS (HR, 0.848; 95% CI, 0.510-1.410), a substantially reduced risk of radiographic progression (HR, 0.386; 95% CI, 0.259-0.577), improved 12-month OS (65.1% vs 55.3%) and rPFS (30.9% vs 8.2%) rates, increased time to PSA progression (HR, 0.358; 95% CI,, and a better PSA response rate (52.1% vs 4.9%) compared with those who received placebo. No increase in treatment-related adverse events was observed for the visceral metastases cohort compared with the nonvisceral metastases cohort. CONCLUSIONS: Across multiple endpoints, patients who have visceral metastases have better outcomes with enzalutamide than with placebo. Cancer 2017;123:253-62.
INTRODUCTION
Prostate cancer is the second most common malignancy in men worldwide (1, 095 ,000 cases in 2012) and the most common male malignancy in the United States (220,800 new cases estimated in 2015). 1, 2 An estimated 22% of patients in the United States and a majority of patients in northeast China who are diagnosed with prostate cancer have locally advanced or metastatic disease at presentation. 3, 4 Patients with metastatic disease are typically treated first with androgendeprivation therapy (ADT) by bilateral orchiectomy (ie, castration) or luteinizing hormone-releasing hormone agonists/ antagonists. Patients with metastatic disease at diagnosis who receive ADT often develop a castration-resistant phenotype within 1 to 3 years. 5, 6 Furthermore, the median survival of patients with metastatic castration-resistant prostate cancer (mCRPC) is often less than 3 years with currently available treatments. [7] [8] [9] Visceral metastases are identified in approximately 22% to 30% of patients with mCRPC [10] [11] [12] [13] and are associated with unfavorable outcomes. 14, 15 Historically, patients with visceral (liver and lung) involvement have been considered as a single group; however, several recent studies have demonstrated that the prognostic significance of spread to these sites differs, with spread to the liver associated with inferior survival.
In phase 1 and 2 clinical trials, enzalutamide was associated with tumor responses and had a favorable safety profile, 18 which led to the phase 3 multinational AFFIRM trial in patients (N 5 1199) with mCRPC who had previously received treatment with docetaxel. 19 At the interim analysis of that trial, enzalutamide reduced the risk of death by 37% relative to placebo (P < .001). Consequently, the independent data and safety monitoring committee recommended that the study be halted and unblinded, and the patients who were receiving placebo were offered enzalutamide. 19 In the current study, we performed prespecified secondary and post hoc analyses of outcomes in patients from the AFFIRM trial with visceral disease who were considered separately (liver vs lung); efficacy and safety are reported using early indicators of response and later indicators of disease progression, as outlined in Prostate Cancer Clinical Trials Working Group 2 (PCWG2) recommendations. 20 
MATERIALS AND METHODS

Study Population
Eligibility criteria for AFFIRM were previously described in detail. 19 In brief, patients were eligible if they had histologically or cytologically confirmed prostate cancer, had castrate levels of testosterone, had received docetaxel treatment, and had progressive disease defined according to PCWG2 criteria. 20 All patients provided written informed consent to participate in the study.
Study Design and Treatment
AFFIRM was an international, randomized, doubleblind, placebo-controlled phase 3 study (clinicaltrials.gov identifier NCT00974311) comparing the efficacy of enzalutamide versus placebo in men with mCRPC after docetaxel therapy. 19 Review boards of all participating institutions approved the study, which was conducted according to the provisions of the Declaration of Helsinki and Good Clinical Practice Guidelines of the International Conference on Harmonisation. After stratification according to Eastern Cooperative Oncology Group (ECOG) performance status (0 or 1 vs 2) and mean pain score (0-4 vs 4), patients were randomly assigned 2:1 to receive either enzalutamide capsules 160 mg daily or matching placebo. The receipt of prednisone or other glucocorticoids during treatment was permitted but not required. Study drug was administered until further systemic treatment was initiated after disease progression. The primary study endpoint, overall survival (OS), and all secondary endpoints were previously defined. 19 For the current prespecified secondary and post hoc analyses, the cohort of patients with established visceral metastases in the liver or lung at baseline was selected independent of skeletal or lymph node involvement. These cohorts were compared with the remaining population of patients without specific liver or lung metastases, who may have presented with bone and/or lymph node involvement and/or metastases at alternative soft tissue sites; the latter cohort is hereinafter termed the nonvisceral metastases cohort. Because liver metastases have been previously identified to have a strong correlation with negative outcomes, 11, 14, 16 in the prespecified analysis of OS comparing patients with liver versus lung metastases independent of treatment arm and in the exploratory post hoc analyses, patients with both liver and lung metastases were included solely in the liver metastases cohort.
The outcomes measured included confirmed posttherapy prostate-specific antigen (PSA) changes, including the proportion of patients with PSA declines 50% from baseline; the objective response rate (ORR) in measurable soft tissue disease (the best overall radiographic response according to Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v1.1]
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; the time to PSA progression; radiographic progression-free survival (rPFS) (according to RECIST v1.1 for soft tissue disease and PCWG2 20 ; and OS.
Statistical Analysis
Primary endpoint
Survival was calculated from the start of therapy to the status of each patient at the data cutoff date of September 25, 2011. Hazard ratios (HRs) were determined using the Cox regression model (with treatment as the only covariate) without stratification and are relative to enzalutamide, with values <1 favoring enzalutamide.
Secondary endpoints
The proportion of patients with PSA declines 50% from baseline and the best overall radiographic response rates were analyzed using the Cochran-Mantel-Haenszel mean score test stratified by 2 randomization stratification factors (ECOG performance status and mean pain score). The time to PSA progression and rPFS were based on the earliest contributing event censored at the date of last assessment and were analyzed using the log-rank test and Cox regression model. patients with visceral liver and/or lung metastases who received either enzalutamide or placebo. The interaction between enzalutamide treatment and the presence of visceral metastases (liver and/or lung) were examined for rPFS and OS. These were unplanned post hoc analyses, and no adjustments were made for multiple comparisons.
RESULTS
Patients
Of 1199 patients who were randomized in the AFFIRM trial (enzalutamide, n 5 800; placebo, n 5 399), 278 (23.2%) had liver and/or lung metastases at baseline (Fig.   1 The liver metastases cohort generally had more adverse prognostic factors than the nonvisceral and lung metastases cohorts (Table 1 ). In contrast, the lung metastases cohort exhibited baseline characteristics comparable to those of the nonvisceral metastases cohort, with the exception of the number of bone metastases, which was higher in patients who had lung metastases.
The median duration of study drug treatment for the nonvisceral metastases cohort was 9.3 months (range, 0.1-23.2 months) for those receiving enzalutamide (n 5 604) and 3.1 months (range, 0.2-19.6 months) for those receiving placebo (n 5 317). Treatment duration in the liver metastasis cohort was lower, at 4.0 months (range, 0.0-17.5 months) in the enzalutamide group and 2.7 months (range, 0.2-20.7 months) in the placebo group. In contrast, treatment duration in the lung metastasis cohort was similar to that in the nonvisceral metastases cohort, at 8.3 months (range, 0.4-21.2 months) and 3.5 months (range, 0.2-17.0 months), respectively.
Efficacy
PSA and objective tumor response
A significantly higher proportion of patients with liver disease had PSA declines 50% from baseline with enzalutamide than with placebo (35.1% vs 4.8%; 95% confidence interval [CI], 16.2%-44.6%), as did those with lung disease (52.1% vs 4.9%; 95% CI, 35.2%-59.3%) (Fig. 2 , Table 2 ). Similarly, enzalutamide was associated with an increase in ORR compared with placebo in both the liver and lung metastases cohorts.
Time to PSA progression
In the liver metastases cohort, the median time to PSA progression was modestly shorter with enzalutamide than with placebo. In the lung metastases cohort, enzalutamide considerably improved the time to PSA progression compared with placebo (HR, 0.358; 95% CI, 0.204-0.627) ( Table 2) .
rPFS
Enzalutamide extended the median rPFS by 2.6 months (HR, 0.505; 95% CI, 0.377-0.676) (Fig. 3a) and increased the 12-month rPFS rate by 15.3% (21.5% vs 6.2%) relative to placebo in patients with liver and/or lung metastases (Fig. 3a) . At 6 months, 61.1% and 17.8% of enzalutamide-treated and placebo-treated patients in the overall population, respectively, were receiving drug; 24.8% and 4.5%, respectively, were still receiving drug at 12 months. rPFS also improved in patients with nonvisceral metastases who were receiving enzalutamide versus placebo (HR, 0.360; 95% CI, 0.304-0.425; 12-month rPFS rate, 36.0% vs 9.5%). A post hoc test of the interaction between enzalutamide treatment and visceral status was not significant (P 5 .1947) for rPFS. Enzalutamide improved rPFS in both visceral metastases cohorts, but the improvement was greater in patients with lung metastases than in those with liver metastases (Fig. 4a,b , Table 2 ).
OS
The median duration of follow-up to determine survival status in the AFFIRM trial was 14.4 months. 19 Enzalutamide extended median OS by 3.9 months (HR, 0.806; 95% CI, 0.574-1.132) (Fig. 3b) and increased the 12-month OS rate by 11.1% (52.1% vs 41.1%) relative to placebo in patients with liver and/or lung metastases. OS also was improved in patients with nonvisceral metastases who were receiving enzalutamide versus placebo (HR, 0.562; 95% CI, 0.457-0.692; 12-month OS rate, 73.2% vs 57.1%) (Fig. 3b) . Regardless of whether patients Original Article received enzalutamide or placebo, median OS times were shorter in patients with liver and/or lung metastases than in patients with nonvisceral metastases (Fig. 3b) . A post hoc test of the interaction between enzalutamide treatment and visceral status was not significant (P 5 .1437) for OS.
To address the impact of metastatic disease distribution, OS was compared in patients with lung versus liver metastases. Patients who had liver metastases had shorter OS (median, 7.7 months; 95% CI, 5.8-9.8 months) than those who had lung metastases alone (median, 16.5 months; 95% CI, 13.8 months to estimate not met; HR, 1.991) (Fig. 3c) . Compared with placebo, enzalutamide was associated with an improvement in median OS of 3.3 months in patients with liver metastases and 1.2 months in patients with lung metastases (Fig. 4c,d , Table 2 ). Enzalutamide was also associated with a 17.1% increase (37.7% vs 20.6%) in the 12-month OS rate among patients with liver metastases and a 9.8% increase (65.1% vs 55.3%) among those with lung metastases (Table 2) .
Safety
In this post hoc analysis, the total number of treatmentemergent adverse events (AEs) was comparable among all 3 subgroups, with 97.7% of patients who had nonvisceral metastases, 97.6% of those who had liver metastases, and 100% of those who had lung metastases presenting with at least 1 treatment-emergent AE of any grade. The proportion of patients who discontinued treatment because of an AE was comparable between the visceral (8.6%) and nonvisceral (8.3%) metastases cohorts. The observed AEs in both enzalutamide-treated and placebo-treated patients who had liver or lung metastases were broadly similar to those observed in patients who had nonvisceral metastases (Table 3) , with some differences. Fatigue was more common in enzalutamide-treated patients who had liver or lung metastases than in those who received placebo, whereas no similar trend was observed in the nonvisceral cohort. Liver function test abnormalities were not common in enzalutamide-treated or placebo-treated patients in any of the visceral metastases subgroups.
DISCUSSION
The primary analysis of the AFFIRM trial demonstrated that patients with visceral metastases had worse outcomes than patients with nonvisceral metastases but benefited from treatment with the AR inhibitor enzalutamide. 19 These data are extended here to evaluate the relation between specific metastatic sites (liver vs lung) and efficacy and safety findings from AFFIRM. The results with enzalutamide confirm that the prognosis of patients with liver and lung disease were distinctly different; however, clinical benefit was observed in both cohorts, including in the proportion of patients who had a PSA decline 50% from baseline, and improved ORR and length of rPFS and OS.
Although data on median values and HRs provide valuable exploratory insights into enzalutamide treatment effects, statistical findings should be viewed conservatively given the post hoc nature of these analyses and the small sample sizes, particularly for the cohort of patients with liver metastases. In addition, patients were not prospectively stratified based on the type of metastasis.
In this exploratory analysis, compared with placebo, enzalutamide reduced the risk of death by 19.4% and the risk of progression by 49.5%, and it improved 1-year survival rates by 11.1% and 1-year rPFS rates by 15.3% in patients who had visceral liver and/or lung metastases; greater efficacy was observed with regard to progression in patients who had lung metastases (15.2%, 61.4%, 9.8%, and 22.7%, respectively) than in those who had liver metastases (30.3%, 35.5%, 17.1%, and 8.6%, respectively). This is consistent with data presented as part of exploratory analyses of patients with mCRPC who had visceral metastases and received treatment with abiraterone acetate plus prednisone (vs prednisone alone as an active comparator).
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Although our analyses demonstrate that patients with visceral metastases benefit from enzalutamide, metastatic disease distribution may affect its efficacy, 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ENZA, enzalutamide; mCRPC, metastatic castration-resistant prostate cancer; PBO, placebo.
particularly in patients with liver metastases. Enzalutamide-treated patients with lung metastases saw improvements in both early indicators of response (ie, PSA and tumor response) and later indicators of disease progression, including a 15.2% reduction in the risk of death and an 9.8% increase in the 1-year OS rate (65.1% vs 55.3% with placebo). Men with liver metastases gained more modest benefit with enzalutamide, although enzalutamide was associated with a 30.3% reduction in the risk of death and a 17.1% increase in 1-year OS rates (37.7% vs 20.6% with placebo). These findings are consistent with a retrospective analysis of the phase 3 TAX 327 study of docetaxel plus prednisone or mitoxantrone plus prednisone, which demonstrated that patients with liver metastases had shorter OS than patients with lung metastases, who, in turn, had shorter OS than patients with lymph node disease only. 16 Similarly, in exploratory analyses of patients with mCRPC who received treatment with abiraterone acetate plus prednisone (vs prednisone alone as an active comparator), 11 the median OS was markedly shorter in patients with liver metastases (7.3 months) than in those with lung metastases (13.9 months) in the abiraterone plus prednisone arm and also in the prednisone-alone arm (4.0 and 7.9 months, respectively). Further analyses using larger populations that account for specific patient and tumor biology characteristics and the extent of metastatic spread may help elucidate the factors contributing to outcomes in this severely ill population. Emerging data suggest that specific histologic characteristics, tumor microenvironments, and molecular aberrations in visceral metastatic tumor tissues are associated with resistance mechanisms and survival outcomes. [22] [23] [24] Therapeutic options remain limited for patients who have mCRPC with visceral metastases. Typically, such patients have been excluded from enrolling in phase 2 and 3 clinical trials of new therapies, such as radium-223 dichloride and sipuleucel-T, 25, 26 and ipilimumab has performed poorly in patients with visceral metastases or more significant disease burden. 27, 28 However, cabazitaxel plus prednisone may represent a therapeutic option; this regimen prolonged OS (15.1 vs 12.7 months) and rPFS (2.8 vs 1.4 months) compared with prednisone plus mitoxantrone in patients with mCRPC who had progressed on docetaxel, 24.9% (188 of 755) of whom had visceral metastases at baseline, and efficacy with cabazitaxel was reported even in patients who progressed after abiraterone. 12, 29, 30 Given the prolonged survival times associated with the receipt of novel therapeutics in patients with prostate cancer, it is likely that the number of patients with visceral metastases will continue to increase in clinical practice, 3 making alternative therapeutic options increasingly critical.
In the AFFIRM trial, patients in the visceral metastases cohort did not demonstrate any notable increases in treatment-emergent AEs compared with the nonvisceral metastases cohort, and patient discontinuation because of AEs was comparable between the visceral and nonvisceral metastases cohorts. Patients who had both liver and lung metastases at baseline were included in the liver-only cohort because of the strong correlation of liver metastases with negative outcomes. Although it was possible to identify patients with measurable liver or lung metastases at baseline, others may have had subclinical metastases or lesions that developed during the trial. Furthermore, among patients in the nonvisceral metastases cohort, a small percentage had nonliver, nonlung visceral tumors that were difficult to localize to specific organs. The relatively stringent inclusion and exclusion criteria of this randomized clinical trial may limit potential interpretation and general applicability of these data. However, another phase 3 trial testing enzalutamide versus placebo in patients with earlier stages of mCRPC (PREVAIL) also included a subgroup of patients with visceral metastases, and evidence of enzalutamide efficacy was reported. 8 In conclusion, these data strongly suggest that patients who present with visceral metastases in liver versus lung should be assessed independently given the differential prognosis and response to treatment observed based on the site of visceral disease. Improvements observed with enzalutamide compared with placebo in the visceral metastases cohort highlight the finding that visceral metastases per se should not routinely be used as an exclusion criterion in clinical trials, because this subset of patients can still benefit from treatment.
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